

MINISTRY OF HEALTH & FAMILY WELFARE
Government of India
Through

**RITES Ltd., RITES Office Complex, Annexe Building, MSM Division,
4th Floor, Plot No. 144, Sector - 44 Gurgaon - 122003, (Haryana)-India**

Amendment-2 Dated 12th April 2013

For

Supply of Artesunate Injection Kit (Artesunate IP 60mg + 5% Sodium Bicarbonate Injection Amp + Sodium Chloride Solution Amp) through International Competitive Bidding

Bid Ref. No: RITES/MSM/EPW/NVBDCP/02/2013

Following amendment is made to the bid document for Supply of Artesunate Injection kits:-

<i>Bid Doc. Clause Reference</i>	<i>Existing</i>	<i>Modified</i>
Section II Bid Data Sheet ITB 2.1, pg 38	Schedules I to V are financed by World Bank and schedules VI & VII are financed by GFATM (Global Fund to fight AIDS, Tuberculosis and Malaria).	Schedules I to V are financed by World Bank.
Section II Bid Data Sheet ITB 4.1 & 5.1, pg 39	The schedules financed by GFATM will also be governed by these Guidelines, except where additional requirements of GFATM are indicated in the bid document. The World Bank will not supervise the procurement process for the Schedules financed by GFATM.	Deleted
Section II Bid Data Sheet ITB 7.1(a), pg 40	For the schedules funded by GFATM, an additional requirement is as follows:- The selection of supplier will be as per Global Fund Quality Assurance Policy, as applicable on the date of bid opening. Bidders should submit the relevant documentary evidence in support. Reference may be made to the GFATM website. http://www.theglobalfund.org/en/procurement/pharmaceutical/?lang=en The bidder shall either be prequalified by the World Health Organization (WHO) for the product being offered or products being offered by the bidder	Deleted

<i>Bid Doc. Clause Reference</i>	<i>Existing</i>	<i>Modified</i>																																										
	<p>should be approved (or tentatively approved) or authorized for use by a stringent regulatory authority (a member, observer or associate of ICH) as per GFATM QA policy and the prequalification/approval or authorization will be valid on the date of submission of bid.</p> <p>Other qualification requirement (for schedules funded by WB and GFATM) for Bidders are:</p>																																											
<p>Section II Bid Data Sheet ITB 7.1(a) (A) (i) (f) (1), pg 41</p>	<p>that it has successfully completed at least one similar contract within the period of last five years (preceding two months before the date of bid opening) for supply of goods against the schedule quoted. Value of each completed contract should be as per table below and that include comparable products. Copies of relevant contracts and invoices may be furnished.</p> <table border="1" data-bbox="399 1157 927 1598"> <thead> <tr> <th><i>Sch No</i></th> <th><i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i></th> <th><i>Similar Product</i></th> </tr> </thead> <tbody> <tr><td>I</td><td>1,360,000</td><td>Vials</td></tr> <tr><td>II</td><td>3,140,000</td><td>Vials</td></tr> <tr><td>III</td><td>9,200,000</td><td>Vials</td></tr> <tr><td>IV</td><td>3,380,000</td><td>Vials</td></tr> <tr><td>V</td><td>4,800,000</td><td>Vials</td></tr> <tr><td>VI</td><td>5,140,000</td><td>Vials</td></tr> <tr><td>VII</td><td>3,400,000</td><td>Vials</td></tr> </tbody> </table>	<i>Sch No</i>	<i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i>	<i>Similar Product</i>	I	1,360,000	Vials	II	3,140,000	Vials	III	9,200,000	Vials	IV	3,380,000	Vials	V	4,800,000	Vials	VI	5,140,000	Vials	VII	3,400,000	Vials	<p>that it has successfully completed at least one similar contract within the period of last five years (preceding two months before the date of bid opening) for supply of goods against the schedule quoted. Value of each completed contract should be as per table below and that include comparable products. Copies of relevant contracts and invoices may be furnished.</p> <table border="1" data-bbox="946 1157 1474 1514"> <thead> <tr> <th><i>Sch No</i></th> <th><i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i></th> <th><i>Similar Product</i></th> </tr> </thead> <tbody> <tr><td>I</td><td>1,360,000</td><td>Vials</td></tr> <tr><td>II</td><td>3,140,000</td><td>Vials</td></tr> <tr><td>III</td><td>9,200,000</td><td>Vials</td></tr> <tr><td>IV</td><td>3,380,000</td><td>Vials</td></tr> <tr><td>V</td><td>4,800,000</td><td>Vials</td></tr> </tbody> </table>	<i>Sch No</i>	<i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i>	<i>Similar Product</i>	I	1,360,000	Vials	II	3,140,000	Vials	III	9,200,000	Vials	IV	3,380,000	Vials	V	4,800,000	Vials
<i>Sch No</i>	<i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i>	<i>Similar Product</i>																																										
I	1,360,000	Vials																																										
II	3,140,000	Vials																																										
III	9,200,000	Vials																																										
IV	3,380,000	Vials																																										
V	4,800,000	Vials																																										
VI	5,140,000	Vials																																										
VII	3,400,000	Vials																																										
<i>Sch No</i>	<i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i>	<i>Similar Product</i>																																										
I	1,360,000	Vials																																										
II	3,140,000	Vials																																										
III	9,200,000	Vials																																										
IV	3,380,000	Vials																																										
V	4,800,000	Vials																																										
<p>Section II Bid Data Sheet ITB 7.1(a) (A) (i) (f) (2), pg 42</p>	<p>that it has achieved an actual annual production rate of at least equal to the quantities specified in the following table for each pharmaceuticals/goods i.e. tablets / capsules / vials / syringes / needles under the lot(s) offered for</p>	<p>that it has achieved an actual annual production rate of at least equal to the quantities specified in the following table for each pharmaceuticals/goods i.e. tablets / capsules / vials / syringes / needles under the lot(s) offered for</p>																																										

<i>Bid Doc. Clause Reference</i>	<i>Existing</i>	<i>Modified</i>																																																
	<p>individual schedule, in any one of the last five (05) fiscal years. This figure should be certified by the Chartered Accountant. If the bidder quotes for more than one schedule, the above criteria shall be cumulative.</p> <table border="1" data-bbox="431 495 922 936"> <thead> <tr> <th><i>Schedule No</i></th> <th><i>Actual Annual Production</i></th> <th><i>Similar Product</i></th> </tr> </thead> <tbody> <tr><td>I</td><td>6,800</td><td>Vials</td></tr> <tr><td>II</td><td>15,700</td><td>Vials</td></tr> <tr><td>III</td><td>46,000</td><td>Vials</td></tr> <tr><td>IV</td><td>16,900</td><td>Vials</td></tr> <tr><td>V</td><td>24,000</td><td>Vials</td></tr> <tr><td>VI</td><td>25,700</td><td>Vials</td></tr> <tr><td>VII</td><td>17,000</td><td>Vials</td></tr> <tr><td>Total</td><td>152,100</td><td>Vials</td></tr> </tbody> </table>	<i>Schedule No</i>	<i>Actual Annual Production</i>	<i>Similar Product</i>	I	6,800	Vials	II	15,700	Vials	III	46,000	Vials	IV	16,900	Vials	V	24,000	Vials	VI	25,700	Vials	VII	17,000	Vials	Total	152,100	Vials	<p>individual schedule, in any one of the last five (05) fiscal years. This figure should be certified by the Chartered Accountant. If the bidder quotes for more than one schedule, the above criteria shall be cumulative.</p> <table border="1" data-bbox="979 495 1469 852"> <thead> <tr> <th><i>Schedule No</i></th> <th><i>Actual Annual Production</i></th> <th><i>Similar Product</i></th> </tr> </thead> <tbody> <tr><td>I</td><td>6,800</td><td>Vials</td></tr> <tr><td>II</td><td>15,700</td><td>Vials</td></tr> <tr><td>III</td><td>46,000</td><td>Vials</td></tr> <tr><td>IV</td><td>16,900</td><td>Vials</td></tr> <tr><td>V</td><td>24,000</td><td>Vials</td></tr> <tr><td>Total</td><td>109,400</td><td>Vials</td></tr> </tbody> </table>	<i>Schedule No</i>	<i>Actual Annual Production</i>	<i>Similar Product</i>	I	6,800	Vials	II	15,700	Vials	III	46,000	Vials	IV	16,900	Vials	V	24,000	Vials	Total	109,400	Vials
<i>Schedule No</i>	<i>Actual Annual Production</i>	<i>Similar Product</i>																																																
I	6,800	Vials																																																
II	15,700	Vials																																																
III	46,000	Vials																																																
IV	16,900	Vials																																																
V	24,000	Vials																																																
VI	25,700	Vials																																																
VII	17,000	Vials																																																
Total	152,100	Vials																																																
<i>Schedule No</i>	<i>Actual Annual Production</i>	<i>Similar Product</i>																																																
I	6,800	Vials																																																
II	15,700	Vials																																																
III	46,000	Vials																																																
IV	16,900	Vials																																																
V	24,000	Vials																																																
Total	109,400	Vials																																																
<p>Section II Bid Data Sheet ITB 7.1(a) (A) (i) (f) (3), pg 42</p>	<p>that it has generated an annual turnover of at least of the value as given in table below, during any one of the last three financial years, to qualify for a schedule. If the bidder quotes for more than one Schedule, the above criteria shall be cumulative. The turnover is to be supported by audited financial statements of accounts (including balance sheet, profit and loss account, auditor's reports, and IT returns) for the past three financial years duly certified by the auditor of the Company. If the bidder quotes for more than one schedule, the above criteria shall be cumulative.</p> <table border="1" data-bbox="407 1633 922 1894"> <thead> <tr> <th><i>Schedule No</i></th> <th><i>Annual Turnover (in Indian Rupees or Equivalent)</i></th> </tr> </thead> <tbody> <tr><td>I</td><td>4,080,000</td></tr> <tr><td>II</td><td>9,420,000</td></tr> <tr><td>III</td><td>27,600,000</td></tr> <tr><td>IV</td><td>10,140,000</td></tr> </tbody> </table>	<i>Schedule No</i>	<i>Annual Turnover (in Indian Rupees or Equivalent)</i>	I	4,080,000	II	9,420,000	III	27,600,000	IV	10,140,000	<p>that it has generated an annual turnover of at least of the value as given in table below, during any one of the last three financial years, to qualify for a schedule. If the bidder quotes for more than one Schedule, the above criteria shall be cumulative. The turnover is to be supported by audited financial statements of accounts (including balance sheet, profit and loss account, auditor's reports, and IT returns) for the past three financial years duly certified by the auditor of the Company. If the bidder quotes for more than one schedule, the above criteria shall be cumulative.</p> <table border="1" data-bbox="951 1633 1469 1894"> <thead> <tr> <th><i>Schedule No</i></th> <th><i>Annual Turnover (in Indian Rupees or Equivalent)</i></th> </tr> </thead> <tbody> <tr><td>I</td><td>4,080,000</td></tr> <tr><td>II</td><td>9,420,000</td></tr> <tr><td>III</td><td>27,600,000</td></tr> <tr><td>IV</td><td>10,140,000</td></tr> </tbody> </table>	<i>Schedule No</i>	<i>Annual Turnover (in Indian Rupees or Equivalent)</i>	I	4,080,000	II	9,420,000	III	27,600,000	IV	10,140,000																												
<i>Schedule No</i>	<i>Annual Turnover (in Indian Rupees or Equivalent)</i>																																																	
I	4,080,000																																																	
II	9,420,000																																																	
III	27,600,000																																																	
IV	10,140,000																																																	
<i>Schedule No</i>	<i>Annual Turnover (in Indian Rupees or Equivalent)</i>																																																	
I	4,080,000																																																	
II	9,420,000																																																	
III	27,600,000																																																	
IV	10,140,000																																																	

<i>Bid Doc. Clause Reference</i>	<i>Existing</i>		<i>Modified</i>																																											
	V	14,400,000	V	14,400,000																																										
	VI	15,420,000	Total	65,640,000																																										
	VII	10,200,000																																												
	Total	91,260,000																																												
Section II Bid Data Sheet ITB 7.1(a) (B) (b), pg 44	<p>The bidder has successfully completed at least one similar contract within the period of last five years (preceding two months before the date of opening of bid) for supply of goods against the schedule offered. Value of each completed contract should be at least the value given in the table below that includes similar products e.g. tablets. The bidder will also submit the list of major supply contracts completed and in hand within the last five years as per Form 11 in Section VIII. Copies of relevant supply orders and invoices shall be submitted.</p> <table border="1" data-bbox="436 1056 924 1539"> <thead> <tr> <th><i>Sch No</i></th> <th><i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i></th> <th><i>Similar Product</i></th> </tr> </thead> <tbody> <tr><td>I</td><td>680,000</td><td>Vials</td></tr> <tr><td>II</td><td>1,570,000</td><td>Vials</td></tr> <tr><td>III</td><td>4,600,000</td><td>Vials</td></tr> <tr><td>IV</td><td>1,690,000</td><td>Vials</td></tr> <tr><td>V</td><td>2,400,000</td><td>Vials</td></tr> <tr><td>VI</td><td>2,570,000</td><td>Vials</td></tr> <tr><td>VII</td><td>1,700,000</td><td>Vials</td></tr> </tbody> </table>		<i>Sch No</i>	<i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i>	<i>Similar Product</i>	I	680,000	Vials	II	1,570,000	Vials	III	4,600,000	Vials	IV	1,690,000	Vials	V	2,400,000	Vials	VI	2,570,000	Vials	VII	1,700,000	Vials	<p>The bidder has successfully completed at least one similar contract within the period of last five years (preceding two months before the date of opening of bid) for supply of goods against the schedule offered. Value of each completed contract should be at least the value given in the table below that includes similar products e.g. tablets. The bidder will also submit the list of major supply contracts completed and in hand within the last five years as per Form 11 in Section VIII. Copies of relevant supply orders and invoices shall be submitted.</p> <table border="1" data-bbox="982 1056 1469 1455"> <thead> <tr> <th><i>Sch No</i></th> <th><i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i></th> <th><i>Similar Product</i></th> </tr> </thead> <tbody> <tr><td>I</td><td>680,000</td><td>Vials</td></tr> <tr><td>II</td><td>1,570,000</td><td>Vials</td></tr> <tr><td>III</td><td>4,600,000</td><td>Vials</td></tr> <tr><td>IV</td><td>1,690,000</td><td>Vials</td></tr> <tr><td>V</td><td>2,400,000</td><td>Vials</td></tr> </tbody> </table>		<i>Sch No</i>	<i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i>	<i>Similar Product</i>	I	680,000	Vials	II	1,570,000	Vials	III	4,600,000	Vials	IV	1,690,000	Vials	V	2,400,000	Vials
<i>Sch No</i>	<i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i>	<i>Similar Product</i>																																												
I	680,000	Vials																																												
II	1,570,000	Vials																																												
III	4,600,000	Vials																																												
IV	1,690,000	Vials																																												
V	2,400,000	Vials																																												
VI	2,570,000	Vials																																												
VII	1,700,000	Vials																																												
<i>Sch No</i>	<i>Minimum Value of completed contract (In Indian Rupees or equivalent)</i>	<i>Similar Product</i>																																												
I	680,000	Vials																																												
II	1,570,000	Vials																																												
III	4,600,000	Vials																																												
IV	1,690,000	Vials																																												
V	2,400,000	Vials																																												
Section II Bid Data Sheet ITB 7.1(a) (B) (c), pg 45	<p>The bidder during the last 3 financial years has generated an annual turnover of at least of the value as given in table below, during any one of the last three financial years, to qualify for a schedule. The turnover is to be supported by audited financial</p>		<p>The bidder during the last 3 financial years has generated an annual turnover of at least of the value as given in table below, during any one of the last three financial years, to qualify for a schedule. The turnover is to be supported by audited financial</p>																																											

<i>Bid Doc. Clause Reference</i>	<i>Existing</i>	<i>Modified</i>																																
	<p>statements of accounts (including balance sheet, profit and loss account, auditor's reports, and IT returns) for the past three fiscal years duly certified by the auditor of the Company.</p> <table border="1"> <thead> <tr> <th><i>Schedule No</i></th> <th><i>Annual Turnover (in Indian Rupees or Equivalent)</i></th> </tr> </thead> <tbody> <tr> <td>I</td> <td>2,040,000</td> </tr> <tr> <td>II</td> <td>4,710,000</td> </tr> <tr> <td>III</td> <td>13,800,000</td> </tr> <tr> <td>IV</td> <td>5,070,000</td> </tr> <tr> <td>V</td> <td>7,200,000</td> </tr> <tr> <td>VI</td> <td>7,710,000</td> </tr> <tr> <td>VII</td> <td>5,100,000</td> </tr> <tr> <td>Total</td> <td>45,630,000</td> </tr> </tbody> </table>	<i>Schedule No</i>	<i>Annual Turnover (in Indian Rupees or Equivalent)</i>	I	2,040,000	II	4,710,000	III	13,800,000	IV	5,070,000	V	7,200,000	VI	7,710,000	VII	5,100,000	Total	45,630,000	<p>statements of accounts (including balance sheet, profit and loss account, auditor's reports, and IT returns) for the past three fiscal years duly certified by the auditor of the Company.</p> <table border="1"> <thead> <tr> <th><i>Schedule No</i></th> <th><i>Annual Turnover (in Indian Rupees or Equivalent)</i></th> </tr> </thead> <tbody> <tr> <td>I</td> <td>2,040,000</td> </tr> <tr> <td>II</td> <td>4,710,000</td> </tr> <tr> <td>III</td> <td>13,800,000</td> </tr> <tr> <td>IV</td> <td>5,070,000</td> </tr> <tr> <td>V</td> <td>7,200,000</td> </tr> <tr> <td>Total</td> <td>32,820,000</td> </tr> </tbody> </table>	<i>Schedule No</i>	<i>Annual Turnover (in Indian Rupees or Equivalent)</i>	I	2,040,000	II	4,710,000	III	13,800,000	IV	5,070,000	V	7,200,000	Total	32,820,000
<i>Schedule No</i>	<i>Annual Turnover (in Indian Rupees or Equivalent)</i>																																	
I	2,040,000																																	
II	4,710,000																																	
III	13,800,000																																	
IV	5,070,000																																	
V	7,200,000																																	
VI	7,710,000																																	
VII	5,100,000																																	
Total	45,630,000																																	
<i>Schedule No</i>	<i>Annual Turnover (in Indian Rupees or Equivalent)</i>																																	
I	2,040,000																																	
II	4,710,000																																	
III	13,800,000																																	
IV	5,070,000																																	
V	7,200,000																																	
Total	32,820,000																																	
Section V Special Conditions of Contract GCC 9.1 (a), Pg 82	<p><i>Note:- For the schedules to be financed by GFATM</i></p> <p><i>GFATM may randomly select the samples of finished pharmaceuticals products (FPP) procured under GFATM schedules to be tested for Quality Control (QC) purposes, prior to the delivery of these FPP by the manufacturer to the designated recipients. For further details, bidder may contact the website of the GFATM www.theglobalfund.org/en/procurement/pharmaceutical/?lang=en.</i></p>	Deleted																																
Section V Special Conditions of Contract GCC 23.3, Pg 89	<p>Add the Following</p> <p><i>Note:- For the schedules to be financed by GFATM</i></p> <p><i>GFATM have devised Code of Ethics for suppliers and sanction procedure. Complete guidelines in this regard are available on the GFATM's website. For further details, bidder may contact the website of the GFATM</i></p>	Deleted																																

<i>Bid Doc. Clause Reference</i>	<i>Existing</i>	<i>Modified</i>
	www.theglobalfund.org/en/governance/	
Section VI Schedule of Requirements, Pg 94 & 95	Existing Schedule of Requirements	Revised Schedule of Requirements (refer Annexure – I)
Section VII Technical Specifications (Artesunate Injection Kit) Page 100-109	Existing Technical Specifications of Artesunate Injection Kit in the Bid Document.	Revised Technical Specifications of Artesunate Injection Kit as attached with this amendment as Annexure II.

Schedule of Requirements

<u>WORLD BANK Funded</u>						
Sch No	Item	Consignees	Unit	Qty	Bid Security in INR	Bid Security in US\$
I	Artesunate Inj.	Andhra Pradesh	Nos of Kit	6,800	38,100	700
		Karnataka				
II	Artesunate Inj.	Maharashtra	Nos of Kit	15,700	88,000	1,600
		GMSD Mumbai				
		Gujarat				
III	Artesunate Inj.	Chattisgarh	Nos of Kit	46,000	257,500	4,700
		Jharkhand				
IV	Artesunate Inj.	Madhya Pradesh	Nos of Kit	16,900	95,000	1,750
V	Artesunate Inj.	Orissa	Nos of Kit	24,000	134,500	2,450
		West Bengal				
		GRAND TOTAL		109,400	613,100	11,200

Delivery Schedule: Within 90 days of Notification of Award.

Terms of delivery: For Group 'A' 'B' & 'C' Bidders: To the final destination at the consignee site(s) as per list given below:

Consignee-wise quantity distribution

Sch No	Consignees	Consignee-wise Qty
I	Andhra Pradesh	5,000
	Karnataka	1,800
II	Maharashtra	10,000
	GMSD Mumbai	2,100
	Gujarat	3,600
III	Chattisgarh	24,000
	Jharkhand	22,000
IV	Madhya Pradesh	16,900
V	Orissa	18,000
	West Bengal	6,000
	GRAND TOTAL	109,400

Revised Technical Specifications for Artesunate Injection Kit
(Consisting of total 09 pages)

Technical Specification of Artesunate Injection Kit under NVBDCP

A. Specific requirements

Artesunate Injection Kit consists of a vial of **Artesunate** Injection; an ampoule of 5% Sodium Bicarbonate Injection; an ampoule of Sodium Chloride Solution and Disposable Syringe along with Disposable needle. The individual items contained in the product shall be currently registered in the country of manufacture and shall meet all requirements of the licensing authority of the country of manufacture. The individual items contained in the product shall also be currently registered in India and shall meet all the requirements of the licensing authority in India.

Artesunate Injection:

Description:

Artesunate Injection contains a sterile powder containing Artesunate.

Each vial shall contain -

Artesunate IP 60 mg

Artesunate Injection complies with WHO working document QAS/10.365/FINAL May 2011 (Adopted text for addition to The International Pharmacopoeia) The powder for injection and the reconstituted injection comply with the monograph for "Parenteral Preparations" included in the latest edition of International Pharmacopoeia.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of Sterile Water for Injections, immediately before use.

The quality of Artesunate injection should conform to the requirements of IP or other Pharmacopoeia of equivalent accuracy in case of international transactions.

Labeling:

The label on each vial shall conform to the requirements of I.P and shall appear in the language of English/Hindi. All labeling should be in weatherproof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in IP, all labels shall state the quantity of Artesunate contained in the sealed container, the name of the manufacturer, manufacturing license number, address of manufacturer, lot number, and expiry date. The label shall conform to the requirements of Rule 96 of Drugs & Cosmetic Act.

Packing:

Primary Package:

5 ml Vial (IP type 1 clear)(Containing Artesunate Powder for injection) closed with 20 mm Bromobutyl Rubber Plug and Sealed with flip off seal and plastic overcap.

Sodium Bicarbonate Injection:

Description:

A clear, colourless solution.

Each ampoule shall contain 1 ml of Sodium Bicarbonate Injection (5%W/v).

The quality of Sodium Bicarbonate and Sterile Water for Injection should conform to the requirements of IP. If not mentioned in IP then other Pharmacopoeia of equivalent accuracy in case of international transactions may be followed.

Labelling:

The label on each ampoule shall conform to the requirements of I.P and shall appear in the language of English/Hindi.

All labelling should be in weatherproof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in IP, all labels shall state the name of the manufacturer, manufacturing license number, address of manufacturer, lot number, and expiry date.

Packing:

Primary Package:

IP Type 1 clear plain glass ampoules. Each ampoule shall contain 1 ml of Sodium Bicarbonate injection (5%w/v). The ampoule should be sufficiently transparent to permit visual inspection of the contents.

Sodium Chloride Injection:

Description:

A clear, colourless solution.

Each ampoule shall contain 5 ml of Sodium Chloride Injection (0.9%W/v).

The quality of Sodium Chloride and Sterile Water for Injection should conform to the requirements of IP. If not mentioned in IP then other Pharmacopoeia of equivalent accuracy in case of international transactions may be followed.

Labelling:

The label on each ampoule shall conform to the requirements of I.P and shall appear in the language of English/Hindi.

All labelling should be in weatherproof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in IP, all labels shall state the name of the manufacturer, manufacturing license number, address of manufacturer, lot number, and expiry date.

Packing:

Primary Package:

IP Type 1 clear plain glass/FFS ampoule. Each ampoule shall contain 5 ml of Sodium Chloride injection (0.9%w/v). The ampoule should be sufficiently transparent to permit visual inspection of the contents.

Secondary Package for Artesunate Injection + Sodium bicarbonate Injection + Sodium Chloride Injection:

One vial of Artesunate Injection, one ampoule of Sodium bicarbonate Injection and one ampoule of Sodium Chloride Injection are packed in PVC blisters sealed, thermo-formated trays having high rigidity and sufficient impact strength to provide break resistance packaging.

The tray along with **Instructions for reconstitution and administration of Artesunate Injection** should be packed in a box for easy handling, transport and distribution. It shall be fabricated from Millboard/ grey board/ cardboard with a minimum of bursting strength of 300gsm.

Labelling for secondary packaging:

A label must be affixed either on the top and/or front surface of the secondary package. It should indicate number of boxes of Artesunate injection + Sodium Bicarbonate Injection + Sodium Chloride Injection. Separately the name of the manufacturer, batch number, date of manufacture, date of expiry of Artesunate Injection, Sodium Bicarbonate Injection and Sodium Chloride Injection should be given. The master batch number of the Kit along with Date of Expiry should be given. The label should also give Storage requirements. The label shall conform to the requirements of Rule 96 of Drugs & Cosmetic Act.

Quality Assurance:**Compliance:**

The Supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of the specification and related documents; (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purposes made known to the Seller (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per WHO GMP requirements.

Evidence:

The Supplier shall provide objective evidence, acceptable to the Purchaser, of the satisfaction of the requirements of this document for which no specific inspection has been mentioned.

The Supplier shall provide a copy of the manufacturing record and procedures to the Purchaser for each lot intended for shipment.

The Supplier shall provide a copy of the Certificate of Analysis for each lot intended for shipment.

The Supplier shall provide to the Purchaser a copy of the approval on demand of each source material, constituent material and component for each lot intended for shipment.

The test data for raw materials including water for injection, glass container, in-process, finished product and packaging material testing must be on record for each lot shipped and must be made available to Purchaser's representatives when requested.

Details of samples lifted for testing (such as Millboard/Greyboard boxes, batch no. etc;) should be pasted on the packing of 5 Ply Shipper and records to this effect to be made available to the purchaser

Disposable Syringe and Disposable Needle:**Description (Disposable Syringe):**

Disposable Syringes are Sterile Hypodermic Syringes for Single Use and are fabricated from **virgin** plastic. They shall conform to the standards given in IS 10258:2002. These are medical device intended for immediate use for administration of injectable preparations. They are supplied sterile and pyrogen – free and not to be re-sterilised or reused.

The plastics and elastomer materials (**polypropylene and polyethylene**) of which the barrel and piston are made comply with the relevant specifications issued by BIS. The Syringes comply with the following standards regarding Dimensions including dead volume.

Capacity of the Syringe ml	Tolerance eq. or ex. to cap.	Tolerance < half of cap.	Max. Dead Vol. ml	Length of long Graduation Mark, mm	Overall length of scale, mm	Scale Interval ml	Increment. Between Graduation lines ml
05	+_4% of expelled vol	+_1.5% nominal Cap, +1% of expelled	0.075	8	36	0.50	1

Polydimethylsiloxane (Silicone Oil) is applied to the internal walls of the barrel to assist in the smooth operation of the syringe but no excess be ensured capable of contaminating the contents at the time of use.

Description (Disposable Needles):

Sterile Hypodermic Needles for Single Use comprise of a length of hypodermic grade stainless steel tube connected to a hub that is designed to mate with a syringe or an IV set. They shall conform to the standards given in IS 10654:2002. The other end of the tube is sharpened at the tip as per IS requirements. The tube is covered with a shield made from polypropylene. The hub fabricated from poly propylene is colour coded as per the requirements of ISO 6009. The union of the hub and needle tube is carried out with epoxy adhesive. This medical device in conjunction with Syringe is intended for immediate use for administration of injectable preparations. They are supplied sterile and pyrogen – free and not to be re-sterilised or reused.

The Hypodermic needles shall comply with the following standards regarding Dimensions:

Needle Gauge	Colour of the hub	Nominal Length of the tube mm	Tolerance In length mm	Nominal outside diameter Of needle mm	Diameter of stylet for normal walled tubing mm
23	Blue	25	+ 1, -2	0.6	0.25

Labeling:

The label on each strip shall conform to the requirements of I.P and shall appear in the language of English/Hindi.

All labeling should be in weatherproof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in Drugs & Cosmetic Act 1940 and rules there under, following information should be available:

- A description of the syringe including the capacity/ A description of the Needle including the Gauge and the nominal length
- The word 'Sterile'
- That the syringe/needle is for single use only
- A solvent incompatibility
- The batch number

- Name and address of the manufacturer
- Date of Manufacture and Date of Expiry
- Warning that the syringe is not to be used if the packaging is damaged or sterility protector is loose
- CE marking
- ISO symbol for “do not re-use”

Labeling for secondary packaging:

Secondary Package:

A label must be affixed either on the top and/or front surface of the secondary package. It should indicate:

- A description of the syringe including the capacity and the type of nozzle/ A description of the needle including the gauge and the nominal length
- Quantity of primary packages
- The word ‘Sterile’
- That the syringe is for single use only
- The batch number
- The date (month and year) of sterilization
- Name and address of the manufacturer
- Date of Manufacture and Date of Expiry
- Information for handling, storage and transportation

Quality Assurance:

Compliance:

The Supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of the specification and related documents; (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purposes made known to the Seller (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per cGMP included in Schedule M - III. (f) the product is WHO pre-qualified and (g) the product should conform to ISO 13485.

Evidence:

The Supplier shall provide objective evidence, acceptable to the Purchaser, of the satisfaction of the requirements of this document for which no specific inspection has been mentioned.

The Supplier shall provide a copy of the manufacturing record and procedures to the Purchaser for each lot intended for shipment.

The Supplier shall provide documentary evidence that the sterilization of the syringes has been carried out by validated sterilization procedures (with appropriate controls and recording devices) in case it has been carried out in their premises. If the facilities of other institution are used for sterilization, the approval of the licensing authority and documentary evidence for validated sterilization procedure should be made available.

The supplier shall provide documentary evidence that the inks, glues and adhesives for the marking on the package and on the assembly of the syringe and its package (Wherever necessary) do not migrate across the walls.

The supplier shall provide documentary evidence in regards to bio-compatibility of the device as per the requirements given in "Biological Evaluation of Medical Devices" IS 12572.

The supplier shall provide a certificate of analysis of Polydimethylsiloxane (used for lubrication) conforming to the requirements of IP.

The supplier shall provide a copy of CE certificate.

The Supplier shall provide a copy of the Certificate of Analysis for each lot intended for shipment

Packing:

Primary Package:

Each syringe and needle shall be packed and sealed separately in a primary container. The material of each container should not have detrimental effects on the contents. The material and design should be such as to ensure:

1. The maintenance of sterility under dry, clean and adequately ventilated storage conditions;
2. The minimum risk of contamination of the contents during opening of the container and removal of the contents;
3. Adequate protection of the contents during normal handling, transit and storage;
4. That once opened, the container cannot be easily resealed, and it should be obvious that the container has been opened.

Paper-PVC Blister:

- PVC Film: Transparent, clear, food grade, blister forming PVC film, film gauge- 200microns, PE coating: 25 microns.
- Hard tempered Blister paper, VMCH coated, Thickness: 0.025mm

Secondary Package:

The primary package should be packed in boxes for easy handling, transport and distribution. The box may contain --- primary packages. It shall be fabricated from Millboard/ grey board/ cardboard with a minimum of bursting strength of 400gsm.

B. Inspection:

The Purchaser may inspect and sample, or cause to be sampled, the product at the Supplier's factory and/or warehouse at a mutually agreeable time prior to the shipment of the product.

C. Testing::

The Purchaser may cause independent laboratory testing to be performed as deemed necessary to assure that the goods conform to the prescribed requirements. The said laboratory testing shall be of the Purchaser's choice if suitably equipped and qualified to conduct quality assurance tests on the product.

D. Labelling on Shipper Package:

The external surface of insulated packages should be either white or in the natural color of corrugated carton.

The labels on tertiary packaging must be attached to at least two sides.

The label should include the name of the product, the number of secondary package (boxes) of Artesunate Injection + Sodium Bicarbonate Injection + Sodium Chloride Injection and Disposable Syringes plus Disposable Needles, the name of the manufacturer, Mater batch number and date of expiry.

The label shall include bar code and be tear proof to be pasted on smooth surface to enable it to be read by bar code reader.

E. Packing for Shipper Package:

The secondary packages of Artesunate Injection + Sodium Bicarbonate Injection + Sodium Chloride Injection and that of Syringes + needles shall be packed in weather resistant triple walled insulated corrugated 5-ply cartons, each ply having strength of minimum 150gsm. It should be fabricated from virgin quality 'A' grade material. Burst factor of individual ply should be not less than 22. GSM of the shipper should be not less than 13 Kg/cm². Overall dimensions of the carton should be such that the product does not get damaged during transportation and storage.

F. Shelf Life of Artesunate Injection Kit:

Minimum 24 months, at least 3/4th of the shelf life must remain at the time of shipment. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package

The expiry date of the Artesunate Injection Kit shall be the same as that of Artesunate Injection being the constituent of product with the shortest shelf life.

G. Numbering of shipper packaging:

All boxes should be numbered consecutively. Shipping documents should be included in the box labeled number 1 (consignee wise),

H. Qualification of the Manufacturer:

The Bidder shall furnish a certificate from the competent Regulatory Authority that the manufacturer of the pharmaceutical product is licensed to manufacture these products. The manufacturing facility must conform to WHO-GMP standards. In case of medical devices the manufacturing facility must conform to the standards given in ISO 13485 and Schedule M-III of Drugs & Cosmetic Act.

I. Recalls:

If products must be recalled because of problems with product quality or adverse reactions to the drug, the Supplier will be obliged to notify the purchaser providing full details about the reason leading to the recall and shall take steps to replace the product in question at its own cost with a fresh batch of acceptable quality, or withdraw and give a full refund if the product has been taken off the market due to safety problems.

J. Model Inserts:

An insert containing information in regards to adverse drug reactions and precautions (to be observed while taking the drug) of all the drugs included in the product should form part of each secondary pack.

K. Colour Coding:

The labels on secondary packing and shipper package shall be identified by WHITE background.

L. Bar Coding:

Bar code shall be used to track down the product. It shall be printed on the label of Shipper containing

1. Product identification(GTIN 14) using application identifier (01)
2. Expiry Date in YYMMDD format & using application identifier (17)
3. Master batch number using application identifier (10)

Complete details on GS1 standards along with technical guidelines can be downloaded from www.gs1india.org or www.gs1.org

M. Documentation

Supplier shall provide to Purchaser a copy of the batch record, including all quality assurance documentation for the product being supplied.

Advance notice of arrival and advance shipping documentation:

Copies of the documentation for the goods to be shipped must be sent at least seven days in advance of arrival of the shipment. In the case of an individual contract for a specific destination that requires a longer period of advance notice, a longer period should apply. The consignee(s) shall be intimated well in advance by registered letter/e-mail/ telephone, so that the products are collected from the airport immediately after arrival.

The documentation must include the following:

- Pre-advice defined by the Purchaser
- Airway bill (AWB);
- Supplier's invoice;
- Packing list;
- Lot release certificate (LRC) as per the requirements issued by the national regulatory authority (NRA) of the country of manufacture for each lot and
- Any other document, certificate or instruction specified in the individual order.

The documents shall be sent by e-mail and fax by the freight forwarder or the manufacturer to the consignee, the Purchaser, and any other parties specified in the individual contract.

The pre-advice must contain the following information:

- Purchase order reference;
- Consignee requisition reference;
- Number of packages and gross weight (in kilograms).
- Value of shipment (in Indian Rupees and US \$);
- AWB and flight number(s);
- Date and time for place of departure, transit (if applicable), and arrival;
- Instructions for collection;
- Any other information specified in the individual contract must also be included for the consignee.

The following information shall be stated on the airway bill:

- Consignee's name, address, telephone number (including mobile no.) and e-mail ID.
- Purchase order reference;
- Consignee's requisition reference;
- Instructions to: "Telephone consignee upon arrival (*repeat telephone number*);

N. Dispatch:

Shipments should be scheduled to arrive outside weekends and/or public holidays in the country and airline bookings should be made well ahead of the date of departure.

Dated: 5th April 2013